RecruitingNot ApplicableNCT06244199

Transition to Cardiac Rehabilitation (T2CR) to Address Barriers of Multimorbidity and Frailty


Sponsor

VA Office of Research and Development

Enrollment

250 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Cardiac rehabilitation (CR) is a secondary prevention program for patients with cardiovascular disease (CVD). It is especially valuable as CVD increasingly occurs in combination with comorbidity, frailty, and complexities of care that predispose patients to functional decline, disability, and high costs. Still, few Veterans participate in CR, in part because of the difficult logistics to attend. Promising Practice home-based CR (HBCR) was developed to increase CR participation, but many Veterans remain too limited by comorbidity and frailty for participation. A Transition to CR (T2CR) intervention is a face-to-face program that fosters vital skills, education, insights, motivation, and patient-provider relationships conducive to successful HBCR thereafter. This study compares Veterans eligible for CR who are randomized to T2CR intervention versus usual care. Differences in functional capacity, HBCR participation, and healthy days at home are compared over one year. Patients' experiences and providers' perspectives of barriers and facilitators to T2CR are also compared.


Eligibility

Min Age: 18 Years

Inclusion Criteria7

  • Eligible candidates will consist of male and female Veterans hospitalized with:
  • ischemic heart disease (acute myocardial infarction or stable ischemia)
  • revascularization (coronary artery bypass grafting or percutaneous coronary intervention)
  • valvular heart disease (surgical or percutaneous intervention for mitral regurgitation or aortic stenosis)
  • or heart failure (with reduced or preserved ejection fraction)
  • All will be recruited while initially hospitalized and must express willingness to consider cardiac rehabilitation as a treatment option, including the possibility of the intervention which could possibly extend the length of their hospitalization (for 2 days maximum).
  • Study candidates must also be English speaking and able to provide written informed consent

Exclusion Criteria5

  • Veterans with unstable medical condition as indicated by history, physical exam, and/or laboratory findings end-stage disease likely to be fatal within 12 months
  • severe cognitive impairment (MiniCog score 0-2)
  • history of addictive or behavioral issues that confound safe administration of HBCR
  • hearing loss that interferes with participation in the trial
  • living in a long-term care living situation prior to the time of hospitalization, no plans to return to independent living after the hospitalization

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALT2CR Intervention

The T2CR intervention entails two phases. T2CR Phase 1 (Assess and Plan) is a program that occurs during or shortly after hospital discharge that includes completion of a comprehensive risk assessment, development of strategies to address identified risks while restoring function through education regarding living a healthy lifestyle and familiarization and practice of exercise training techniques. T2CR Phase 2 (Implementation and Support) entails a HBCR program that is based on the Promising Practices HBCR but further enriched by insights and strategies developed in T2CR Phase 1 and which also incorporates techniques that maximize the effectiveness and efficiency of exercise training.

OTHERUsual Care

Participants will receive usual care following an acute heart event that is recommended by their providers, which may include Promising Practices Home-Based Cardiac Rehabilitation (aka Usual HBCR) at both sites or site-based CR at VAPHS.


Locations(2)

VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA

Boston, Massachusetts, United States

VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA

Pittsburgh, Pennsylvania, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06244199


Related Trials